- Home
- PSF vs CATX Comparison
PSF vs CATX Comparison
Compare PSF & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- CATX
- Stock Information
- Founded
- PSF 2010
- CATX 1983
- Country
- PSF United States
- CATX United States
- Employees
- PSF N/A
- CATX N/A
- Industry
- PSF Investment Managers
- CATX Medical/Dental Instruments
- Sector
- PSF Finance
- CATX Health Care
- Exchange
- PSF Nasdaq
- CATX Nasdaq
- Market Cap
- PSF 236.8M
- CATX 239.0M
- IPO Year
- PSF N/A
- CATX N/A
- Fundamental
- Price
- PSF $20.31
- CATX $3.97
- Analyst Decision
- PSF
- CATX Strong Buy
- Analyst Count
- PSF 0
- CATX 11
- Target Price
- PSF N/A
- CATX $12.90
- AVG Volume (30 Days)
- PSF 25.0K
- CATX 1.3M
- Earning Date
- PSF 01-01-0001
- CATX 08-11-2025
- Dividend Yield
- PSF 7.69%
- CATX N/A
- EPS Growth
- PSF N/A
- CATX N/A
- EPS
- PSF N/A
- CATX N/A
- Revenue
- PSF N/A
- CATX $1,471,000.00
- Revenue This Year
- PSF N/A
- CATX N/A
- Revenue Next Year
- PSF N/A
- CATX N/A
- P/E Ratio
- PSF N/A
- CATX N/A
- Revenue Growth
- PSF N/A
- CATX N/A
- 52 Week Low
- PSF $16.00
- CATX $1.60
- 52 Week High
- PSF $20.19
- CATX $16.55
- Technical
- Relative Strength Index (RSI)
- PSF 70.47
- CATX 61.19
- Support Level
- PSF $20.28
- CATX $3.33
- Resistance Level
- PSF $20.44
- CATX $3.69
- Average True Range (ATR)
- PSF 0.12
- CATX 0.38
- MACD
- PSF 0.02
- CATX 0.01
- Stochastic Oscillator
- PSF 81.94
- CATX 64.23
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.